Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
Courtney D D DiNardoCurtis A LachowiezKoichi TakahashiSanam LoghaviLianchun XiaoTapan Mahendra KadiaNaval G DaverMaria AdeotiNicholas James ShortKoiji SasakiSa WangGautam BorthakurGhayas IssaAbhishek MaitiYesid AlvaradoNaveen PemmarajuGuillermo Montalban BravoLucia MasarovaMusa YilmazNitin JainMichael AndreeffElias J JabbourGuillermo Garcia ManeroSteven Mitchell KornblauFarhad RavandiMarina Y KonoplevaHagop M KantarjianPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin + venetoclax represents an effective intensive treatment regimen in ND-AML and R/R-AML patients, associated with deep remissions and a high rate of transition to successful transplantation.
Keyphrases
- acute myeloid leukemia
- newly diagnosed
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- prognostic factors
- chronic lymphocytic leukemia
- stem cells
- acute lymphoblastic leukemia
- low dose
- diffuse large b cell lymphoma
- high dose
- cell therapy
- peripheral blood